Abstract
In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Current Pharmaceutical Design
Title: Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans
Volume: 7 Issue: 14
Author(s): Christopher J. de Souza and Bryan F. Burkey
Affiliation:
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Abstract: In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
de Souza J. Christopher and Burkey F. Bryan, Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans, Current Pharmaceutical Design 2001; 7 (14) . https://dx.doi.org/10.2174/1381612013397339
DOI https://dx.doi.org/10.2174/1381612013397339 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteopontin in CardioMetabolic Medicine: A Risk Stratification
Biomarker with Future Therapeutic Implication
Current Medicinal Chemistry Role of Mitochondria on Muscle Cell Death and Meat Tenderization
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunization Against Active Ghrelin Using Virus-Like Particles for Obesity Treatment
Current Pharmaceutical Design The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern β-Amyloid Apoptotic Injury of Microglia
Current Neurovascular Research Deciphering a Serum Peptide Activity Associated with Biologic Clock
Protein & Peptide Letters Ageing as a Trait de Union Between Diabetes and Dementia for Frailty
CNS & Neurological Disorders - Drug Targets Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Bullous Pemphigoid and Neurologic Diseases: Toward a Specific Serologic Profile?
Endocrine, Metabolic & Immune Disorders - Drug Targets Antimicrobial and Cytotoxicity Activities of 2-(aryl)-3-(benzo[d][1,3] dioxol-5-yl)thiazolidin-4-ones
Letters in Drug Design & Discovery Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Nutritional Interventions and Considerations for the Development of Low Calorie or Sugar Free Foods
Current Diabetes Reviews Female Infertility and Antioxidants
Current Women`s Health Reviews Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Protein Arginine Methyltransferase 1 and its Dynamic Regulation Associated with Cellular Processes and Diseases
Protein & Peptide Letters Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Cognitive Enhancement: Are we Barking Up the Wrong Tree?)
Current Drug Abuse Reviews Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs
Current Drug Metabolism